Changes in the Epidemiology of Hepatocellular Carcinoma in Asia

Liu, Yao; Liu, Lianxin

doi:10.3390/cancers14184473

Cited by 35 publications

(19 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of HCC varies geographically, which may be due to differences in predisposing factors that increase the risk of HCC. 14,15 significant correlation between the expression of SYT12, GATM and FN1 in patients with early onset HBV-related HCC, whereas there was a significant correlation in the expression of STAT1, ALB, MLL4 and TERT in patients with late onset HCC. 39 Additionally, HBV induces HCC formation through the activation or deactivation of various tumorigenic pathways.…”

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 92%

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

et al. 2023

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. The incidence of HCC is affected by genetic and non‐genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT‐rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6‐phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E‐cadherin, have been shown to contribute to the occurrence of HCC. Non‐genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non‐alcoholic fatty liver disease (NAFLD), increase the risk of HCC.Recent FindingsThe severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non‐minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non‐Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC.ConclusionAssessment and treatment of HCC must be consistent using evidence‐based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.

show abstract

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 92%

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Since the 1990s, The World Health Organization (WHO) has called for the formulation of several global public plans (routine HBV vaccine injection, fast virus testing, advanced antiviral therapies) to prevent HBV infection and HBV-related disease progression (1,(20)(21)(22)(23)(24)(25). Most recently, the global HBV infection burden was assessed by Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 collaborators (1) (Figure 2).…”

Section: Epidemiology Of Chronic Hepatitis Bmentioning

confidence: 99%

“…Furthermore, a more significant decline in HBV infection prevalence was observed in younger children (<5 years) (76.8%, 95%UI: 76.2-77.5%) during the same period (1). However, HBV infection and associated diseases burden and progress across the world were markedly disparate, where the developing and poor countries predominated (1,16,21,23,26,27). HBV infection has been endemic in China since the 1980s, where the infant vaccination rate was 99.5% and the timely birth dose vaccination rate was 96% as compared with that in 1992 (28).…”

Section: Epidemiology Of Chronic Hepatitis Bmentioning

confidence: 99%

Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk

Wei

Xia³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The evidence for chronic hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) occurrence is well established. The hepatocyte epithelium carcinogenesis caused by HBV has been investigated and reviewed in depth. Nevertheless, recent findings from preclinical and observational studies suggested that chronic HBV infection is equally important in extrahepatic cancer occurrence and survival, specifically gastrointestinal system-derived cancers. Immune microenvironment changes (immune-suppressive cytokine infiltration), epigenetic modification (N6-methyladenosine), molecular signaling pathways (PI3K–Akt and Wnt), and serum biomarkers such as hepatitis B virus X (HBx) protein are potential underlying mechanisms in chronic HBV infection-induced extrahepatic cancers. This narrative review aimed to comprehensively summarize the most recent advances in evaluating the association between chronic HBV infection and extrahepatic cancer risk and explore the potential underlying molecular mechanisms in the carcinogenesis induction of extrahepatic cancers in chronic HBV conditions.

show abstract

“…Starting by mentioning the most common risk factors of HCC development, such as viral hepatitis B and C and alcohol abuse, it has to be underlined that HCC is attributed ever more to non-viral factors such as non-alcoholic fatty liver disease [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

An Insight into the Arising Role of MicroRNAs in Hepatocellular Carcinoma: Future Diagnostic and Therapeutic Approaches

Koustas

Trifylli²,

Sarantis

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) constitutes a frequent highly malignant form of primary liver cancer and is the third cause of death attributable to malignancy. Despite the improvement in the therapeutic strategies with the exploration of novel pharmacological agents, the survival rate for HCC is still low. Shedding light on the multiplex genetic and epigenetic background of HCC, such as on the emerging role of microRNAs, is considered quite promising for the diagnosis and the prediction of this malignancy, as well as for combatting drug resistance. MicroRNAs (miRNAs) constitute small noncoding RNA sequences, which play a key role in the regulation of several signaling and metabolic pathways, as well as of pivotal cellular functions such as autophagy, apoptosis, and cell proliferation. It is also demonstrated that miRNAs are significantly implicated in carcinogenesis, either acting as tumor suppressors or oncomiRs, while aberrations in their expression levels are closely associated with tumor growth and progression, as well as with local invasion and metastatic dissemination. The arising role of miRNAs in HCC is in the spotlight of the current scientific research, aiming at the development of novel therapeutic perspectives. In this review, we will shed light on the emerging role of miRNAs in HCC.

show abstract

Changes in the Epidemiology of Hepatocellular Carcinoma in Asia

Cited by 35 publications

References 76 publications

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk

An Insight into the Arising Role of MicroRNAs in Hepatocellular Carcinoma: Future Diagnostic and Therapeutic Approaches

Contact Info

Product

Resources

About